natgillin/translations-raw huggingface dataset:
Since mTOR is involved in the control of cell division and the growth of blood vessels, Votubia prevents the division of tumour cells and reduces their blood supply. 
Ker mTOR sodeluje pri nadzoru delitve celic in rasti krvnih žil, zdravilo Votubia preprečuje delitev tumorskih celic in zmanjšuje njihovo oskrbo s krvjo.
Why is Votubia authorised in the EU? 
Zakaj je bilo zdravilo Votubia odobreno v EU?
Side effects reported with Votubia are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Votubia, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Two different dosage regimens of add-on treatment with Votubia (tailored to give lower or higher levels in the blood) were compared with placebo. 
Dva različna režima odmerjanja zdravila Votubia kot dodatka k zdravljenju (prilagojena tako, da se dosežejo višje ali nižje ravni zdravila v krvi) so primerjali s placebom.
What are the risks associated with Votubia? 
Kakšna tveganja so povezana z zdravilom Votubia?
Before treatment, patients had 16 to 17 seizures per week on average and response was considered to be shown by a reduction in seizures of at least 50%. 
Pred zdravljenjem so bolniki imeli v povprečju 16-17 napadov na teden, kot odziv pa se je štelo zmanjšanje števila napadov za vsaj 50 %.
Partial onset seizures 
Napadi parcialnega izvora
When used together with other medicines, e.g. as an add-on treatment for seizures, the dosage may also be affected by the other medicines being taken. 
Ko se uporablja skupaj z drugimi zdravili, npr. kot dodatek k zdravljenju napadov, lahko na odmerek vplivajo tudi druga zdravila, ki so bila vzeta.
Votubia treatment should be started by a doctor experienced in treating tuberous sclerosis and in monitoring levels of medicine in the blood. 
Zdravljenje z zdravilom Votubia mora uvesti zdravnik, ki ima izkušnje z zdravljenjem tuberozne skleroze in s spremljanjem ravni zdravila v krvi.
In renal angiomyolipoma caused by tuberous sclerosis, Votubia has been compared with placebo in one study involving 118 adults. 
Pri ledvičnem angiomiolipomu, ki ga povzroča tuberozna skleroza, so zdravilo Votubia primerjali s placebom v študiji, ki je vključevala 118 odraslih.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Votubia have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Votubia upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Tuberous sclerosis is rare, and Votubia was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 August 2010. 
Tuberozna skleroza je redka bolezen, zato je bilo zdravilo Votubia 4. oktobra 2010 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex'. 
Everolimus se v telesu najprej veže na beljakovino v celicah, imenovano FKBP12, in z njo tvori „skupek“.
The most common side effects with Votubia (seen in more than 1 in 10 patients) are acne, stomatitis (inflammation of the lining of the mouth), upper respiratory tract infections (colds), nasopharyngitis (inflammation of the nose and throat), sinusitis (inflammation of the sinuses), cough, pneumonia (infection of the lung), urinary tract infection, increased blood levels of cholesterol, irregular menstruation (periods), amenorrhoea (absence of periods), headache, diarrhoea, vomiting, rash, tiredness, fever and decreased appetite. 
Najpogostejši neželeni učinki zdravila Votubia (opaženi pri več kot 1 bolniku od 10) so akne, stomatitis (vnetje ustne sluznice), okužbe zgornjih dihal (prehladi), nazofaringitis (okužbe nosu in žrela), sinuzitis (vnetje sinusov), kašelj, pljučnica (okužba pljuč), okužbe sečil, povečane ravni holesterola v krvi, neredne menstruacije, amenoreja (izostanek menstruacij), glavobol, driska, bruhanje, izpuščaj, utrujenost, povišana telesna temperatura in zmanjšan tek.
In patients with renal angiomyolipoma, the recommended dose is 10 mg once a day. 
Pri bolnikih z ledvičnim angiomiolipomom je priporočeni odmerek 10 mg enkrat na dan.
Votubia must not be used in people who are hypersensitive (allergic) to everolimus, to related medicines such as sirolimus and temsirolimus or to any of the other ingredients. 
Zdravila Votubia ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) everolimus, katera koli druga podobna zdravila, kot sta sirolimus in temsirolimus, ali katero koli drugo sestavino zdravila.
It has also shown to be effective at reducing partial-onset seizures associated with tuberous sclerosis. 
Prav tako se je izkazalo za učinkovito pri zmanjševanju števila napadov parcialnega izvora, povezanih s tuberozno sklerozo.
Votubia is used for partialonset seizures (seizures that start in one part of the brain), which may or may not spread to affect the whole brain (secondary generalisation). 
Zdravilo Votubia se uporablja za napade parcialnega izvora (napade, ki se začnejo v enem delu možganov), ki se lahko razširijo na celotne možgane (sekundarna generalizacija) ali ne.
Votubia is a medicine used to treat the following benign (non-cancerous) tumours caused by the genetic disease tuberous sclerosis: 
Votubia je zdravilo, ki se uporablja za zdravljenje naslednjih benignih (nerakavih) tumorjev, ki jih povzroča genetska bolezen, imenovana tuberozna skleroza:
For more information about treatment with Votubia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Votubia preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
mTOR is also thought to play a role in the seizures that occur in patients with tuberous sclerosis but it is not fully understood how the medicine acts to prevent them. 
Za mTOR se predvideva tudi, da sodeluje pri napadih, ki se pojavijo pri bolnikih s tuberozno sklerozo, vendar ni v celoti razumljeno, kako jih zdravilo prepreči.
The main measure of effectiveness was the proportion of patients who responded to treatment and whose brain tumour shrank by at least half after six months of treatment. 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje in katerih možganski tumor se je po šestih mesecih zdravljenja zmanjšal vsaj za polovico.
Votubia contains the active substance everolimus. 
Zdravilo Votubia vsebuje učinkovino everolimus.
This response was seen in 28% (33 of 117 patients) in the lower blood level group and 40% (52 of 130 patients) in the higher blood level group, compared with 15% (18 of 119) of patients taking placebo. 
Ta odziv je bil opažen pri 28 % (33 od 117) bolnikov v skupini z nižjo ravnijo zdravila Votubia v krvi in pri 40 % (52 od 130) bolnikov v skupini z višjo ravnijo zdravila v Votubia v krvi, medtem kot je v skupini, ki je prejemala placebo bil odziv opažen pri 15 % (18 od 119) bolnikov.
The main measure of effectiveness was based on how much the patient's main brain tumour shrank after six months of treatment: the main brain tumour shrank by half in approximately 30% of patients and by about a third in around 70% of patients. 
Glavno merilo učinkovitosti je temeljilo na zmanjšanju bolnikovega glavnega možganskega tumorja po šestih mesecih zdravljenja: glavni možganski tumor se je zmanjšal za polovico pri okoli 30 % bolnikov in za eno tretjino pri okoli 70 % bolnikov.
The European Medicines Agency noted that Votubia has been shown to reduce the size of the brain tumours in adults and children with tuberous sclerosis and that this is expected to reduce the signs and symptoms of SEGA such as seizures, hydrocephalus (accumulation of fluid in the brain), and increased pressure within the brain. 
Evropska agencija za zdravila je menila, da je bilo dokazano, da zdravilo Votubia zmanjšuje velikost možganskih tumorjev pri odraslih in otrocih s tuberozno sklerozo, s čimer naj bi pripomoglo k zmanjšanju znakov in simptomov subependimskega gigantoceličnega astrocitoma, kot so epileptični napadi, hidrocefalus (nabiranje tekočine v možganih) in povišan tlak v možganih.
For more information about using Votubia, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Votubia glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The second study involved 117 patients (including 20 children aged below 3 years) and compared Votubia with placebo (a dummy treatment). 
V drugi študiji je sodelovalo 117 bolnikov (vključno z 20 otroki, mlajšimi od treh let), v njej pa so zdravilo Votubia primerjali s placebom (zdravilom brez zdravilne učinkovine).
In SEGA caused by tuberous sclerosis, Votubia has been studied in two main studies: the first study involved 28 adults and children aged three years and above. 
Zdravilo Votubia so pri bolnikih s subependimskim gigantoceličnim astrocitomom, ki ga povzroča tuberozna skleroza, proučevali v dveh glavnih študijah: v prvo je bilo vključenih 28 odraslih in otrok, starejših od treh let.
The side effects of the medicine were considered to be manageable and were generally mild or moderate. 
Neželeni učinki tega zdravila, ki so na splošno blagi ali zmerni, so bili ocenjeni kot obvladljivi.
The benefits of Votubia as an add-on treatment of partial onset seizures related to tuberous sclerosis that have not been sufficiently controlled by other treatments have been shown in one main study. 
Koristi zdravila Votubia kot dodatka k zdravljenju napadov parcialnega izvora, povezanih s tuberozno sklerozo, ki niso bili ustrezno uravnani z drugimi zdravljenji, so bile predstavljene v eni glavni študiji.
• subependymal giant cell astrocytoma (SEGA), a benign tumour of the brain, where it is used in adults and children whose brain tumour cannot be surgically removed; 
• subependimskega gigantoceličnega astrocitoma (SEGA), tj. benignega možganskega tumorja, pri odraslih in otrocih, pri katerih tumorjev ni mogoče odstraniti s kirurškim posegom;
For SEGA, and for use as add-on treatment of seizures, the starting dose depends on the body surface area (calculated using the patient's height and weight) and the patient's age, but the doctor will adjust the dose based on the patient's blood levels of the medicine and how well the patient tolerates the medicine. 
Začetni odmerek pri subependimskem gigantoceličnem astrocitomu in kadar se uporablja kot dodatek k zdravljenju je odvisen od bolnikove telesne površine (izračunane na podlagi njegove telesne višine in mase) in bolnikove starosti, vendar ga zdravnik lahko prilagodi glede na koncentracijo zdravila v krvi bolnika in glede na to, kako dobro ga ta prenaša.
The main measure of effectiveness was the proportion of patients who responded to treatment and whose kidney tumour shrank by at least half, which was seen in 42% of patients (33 out of 79) treated with Votubia, compared with none of the 39 patients who received placebo. 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje in katerih ledvični tumor se je zmanjšal vsaj za polovico, kar je bilo opaženo pri 42 % (33 od 79) bolnikov, zdravljenih z zdravilom Votubia, medtem ko med 39 bolniki, ki so prejemali placebo, do tega ni prišlo pri nobenem bolniku.
Starting doses may need to be reduced, or treatment avoided, in patients with reduced liver function, depending on how severe this is and on the patient's age and the condition they are being treated for. 
Pri bolnikih z okvaro delovanja jeter bo začetni odmerek morda treba zmanjšati ali se zdravljenju izogniti, odvisno od resnosti težave ter od starosti in stanja bolnika, zaradi katerega se zdravi.
This occurred in 35% of patients (27 out of 78 patients) treated with Votubia, compared with none of the 39 patients who received placebo. 
Do tega je prišlo pri 35 % (27 od 78) bolnikov, zdravljenih z zdravilom Votubia, medtem ko med 39 bolniki, ki so prejemali placebo, do tega ni prišlo pri nobenem bolniku.
The medicine is also used as an add-on treatment in patients from 2 years of age with seizures (fits) related to tuberous sclerosis that have not responded to other treatments. 
Zdravilo se uporablja tudi kot dodatek k zdravljenju pri bolnikih od drugega leta starosti z napadi, povezanimi s tuberozno sklerozo, ki se niso odzvali na druga zdravljenja.
The active substance in Votubia, everolimus, is an anti-tumour medicine that acts by blocking an enzyme called ‘mammalian target of rapamycin' (mTOR), which has increased activity in tumour cells of patients with SEGA or renal angiomyolipoma. 
Zdravilna učinkovina zdravila Votubia, everolimus, je protitumorsko zdravilo, ki deluje tako, da zavira delovanje encima, imenovanega „tarča rapamicina pri sesalcih“(mTOR), ki v tumorskih celicah pri bolnikih s subependimskim gigantoceličnim astrocitomom ali ledvičnim angiomiolipomom deluje s povečanim delovanjem.
For the full list of all side effects reported with Votubia, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Votubia, glejte navodilo za uporabo.
How is Votubia used? 
Kako se zdravilo Votubia uporablja?
How does Votubia work? 
Kako zdravilo Votubia deluje?
Overall, the patients given Votubia had a 29 and 40% reduction respectively in the number of seizures during treatment, compared with a 15% reduction in those given placebo. 
Pri bolnikih, ki so prejemali zdravilo Votubia, je med zdravljenjem prišlo do 29 % oziroma 40 % zmanjšanja števila napadov, v primerjavi s 15 % zmanjšanjem števila napadov pri tistih, ki so jemali placebo.
• renal angiomyolipoma, a benign tumour of the kidneys, where it is used in adults who are at risk of complications but who do not require immediate surgery. 
• ledvičnega angiomiolipoma, tj. benignega tumorja ledvic, pri odraslih, ki so izpostavljeni tveganju za pojav zapletov, vendar takojšnji kirurški poseg pri njih ni potreben.
Votubia has been shown to be effective at treating patients with SEGA and renal angiomyolipoma by shrinking the volume of the tumours. 
Zdravilo Votubia se je izkazalo kot učinkovito pri zdravljenju bolnikov s subependimskim gigantoceličnim astrocitomom in ledvičnim angiomiolipomom, saj je vplivalo na zmanjšanje velikosti tumorjev.
Although surgery remains the standard treatment for this condition, Votubia is expected to benefit patients whose tumour cannot be operated on. Votubia has also been shown to reduce the size of kidney tumours in patients with renal angiomyolipoma and has been shown to be beneficial as an add-on treatment in the management of partial-onset seizures related to tuberous sclerosis that have not sufficiently responded to other therapy. 
Čeprav se ta bolezen običajno zdravi s kirurškim posegom, se pričakuje, da bo zdravilo Votubia koristilo bolnikom, pri katerih tumorja ni mogoče operirati.
This estimate has not been independently verified. 
Ta ocena ni bila neodvisno preverjena.
Some of these cases required hospitalisation. 
V nekaterih primerih je bila potrebna hospitalizacija.
Also the situation is dynamic and may change as new cases arise. 
Prav tako je situacija dinamična in se lahko spremeni z odkritjem novih primerov.
• Avoid contact with eyes. 
• Preprečite stik z očmi.
Maintaining the status quo 
Ohranjanje statusa quo
Secondly, re-formulation would necessitate new quality, safety and efficacy studies, which might not be feasible. 
Drugič, reformulacija bi zahtevala nove raziskave kakovosti, varnosti in učinkovitosti, ki morda niso izvedljive.
- the Committee assessed the information provided by the Marketing Authorisation Holders in response to the list of questions agreed by the Committee on 16 June 2004 and the additional information provided on 12 July 2005; 
- Odbor je ovrednotil podatke, ki so jih predložili imetniki dovoljenja za promet kot odgovor na seznam vprašanj, o katerih se je Odbor sporazumel 16. junija 2004, in dodatne podatke, ki so bili predloženi 12. julija 2005;
Other combinations of measures would theoretically be possible, but would not present significant additional benefits to risk management, and they are therefore not discussed. 
Druge kombinacije ukrepov bi teoretično bile možne, vendar ne predstavljajo znatnih dodatnih koristi k upravljanju tveganja, zato o njih ni bilo razprave.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF MICOTIL (see Annex I) 
ZAKLJUČNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA MICOTIL (glejte Dodatek I)
• Ensure that animals are properly restrained, including those in the vicinity. 
• Zagotovite, da je žival ustrezno zadržana, prav tako morajo biti zadržane živali v bližini.
They tend to be physically active and involved in handling animals every day. 
So telesno dejavni in ravnajo z živalmi vsak dan.
90027 Bernolakova, Slovak Republic 
90027 Bernolakova, Slovaška
D-35396 Gießen 
D-35396 Gießen Nemčija
Cattle and calves up to 2 years of age; 
Govedo in teleta do 2 let starosti;
Harmonised, stringent user safety warnings would include: 
Usklajena obvezna varnostna opozorila za uporabnike bi vključevala:
Survival rates are greatly improved by the correct medical intervention. 
Stopnjo preživetja zelo izboljša pravilna zdravniška pomoč.
In addition this measure would bear a high risk of being ignored. 
Poleg tega bi ta ukrep povečal tveganje ignoriranja ukrepa.
A statement in a frame with yellow background colour, saying: 
Izjava v okvirju z rumeno podlago in naslednjim besedilom:
Accurate weighing of lambs is important to avoid overdosage. 
Natančno tehtanje jagenj je pomembno, da preprečite prekomerno odmerjanje.
It is evident that accidental injections may occur, but normally the volume injected is low. 
Razvidno je, da do nenamernega injiciranja lahko pride, vendar je običajno injicirani volumen majhen.
Stawki no. 2, 21 pietro 00-193 Warsaw Poland 
Stawki no. 2, 21 pietro 00-193 Warsaw Poljska
The product has a relatively long history of use with few questions over its effectiveness in the field. 
Zdravilo ima v praksi relativno dolgo zgodovino uporabe z le nekaj dvomi o njegovi učinkovitosti.
Under paragraph 5.1 “Pharmacodynamic properties” 
Pod točko 5.1 „Farmakodinamične lastnosti“
As tilmicosin persists in tissues for several days, the cardiovascular system should be closely monitored and supportive treatment provided. 
Ker tilmikozin vztraja v tkivih več dni, je potrebno srčno-žilni sistem skrbno nadzorovati in nuditi podporno zdravljenje.
ANNEX IV CONDITIONS OF THE MARKETING AUTHORISATION 
DODATEK IV POGOJI DOVOLJENJA ZA PROMET
- The educational measures for the user are a prerequisite to ensure appropriate adherence to the safety warnings. 
- Izobraževalni ukrepi za uporabnike so predpogoj za zagotovitev primerne doslednosti pri upoštevanju varnostnih opozoril.
Under paragraph 4.4 “Special warnings for each target species” 
Pod točko 4,4 „Posebna opozorila za vsako ciljno živalsko vrsto“
Cattle Sheep (over 15kg) 
Govedo Ovce (težje od 15 kg)
In total 520 human exposures were reported since 1999, of which 509 were accidental. 
Skupno so od leta 1999 poročali o 520 izpostavitvah človeka, od tega je bilo 509 izpostavitev nenamernih.
Do not inject lambs weighing less than 15 kg, since there is a real risk of overdose toxicity. 
Ne injicirajte jagnjem lažjim od 15 kg, saj obstaja resnično tveganje toksičnosti čezmernega odmerka.
In the opinion of the CVMP, this is not a solution in view of the potential risk of accidental fatalities in human beings. 
Po mnenju CVMP to ni rešitev zaradi potencialnega tveganja nezgodnih smrtnih primerov pri ljudeh.
“Special precautions to be taken by the person administering the medicinal product to animals” 
„Posebni varnostni ukrepi, ki jih mora izvajati oseba, ki daje zdravilo živalim“
Of these 509 reports, 214 cases related to non-injection exposures, and 295 to injection exposures, with minor needle scratches being the most common. 
Od teh 509 poročil je bilo 214 primerov povezanih z izpostavitvijo brez injiciranja in 295 primerov povezanih z izpostavitvijo z injiciranjem, pri čemer so bile najpogostejše manjše praske z iglo.
Discussion of risk management options 
Razpravljanje o možnostih upravljanja tveganja
INJECTION OF THIS DRUG IN HUMANS HAS BEEN ASSOCIATED WITH FATALITIES. 
INJICIRANJE TEGA ZDRAVILA V ČLOVEKA JE POVEZANO S SMRTNIMI PRIMERI.
Nevertheless, it is necessary to put in practice some measures to reduce the risks of accidental self-injection. 
Kljub temu je treba v praksi začeti uresničevati nekatere ukrepe za zmanjšanje tveganja nenamernega samoinjiciranja.
Additional data were provided in relation to 4 studies on the likely action mechanism of tilmicosin on the heart function and on possible remedial measures. 
Predloženi so bili podatki v zvezi s 4 raziskavami o verjetnem mehanizmu delovanja tilmikozina na srce in o možnih ukrepih za zdravljenje.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGE ZA DOPOLNITEV POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, KI JIH ZASTOPA EMEA
Withdrawal of the product from the market in the EU 
Umik zdravila iz prometa v EU
However, evidence based data to demonstrate the benefits of Micotil relative to other authorised antibacterials has not been provided. 
Vendar podatki na osnovi dokazov, s katerimi bi bile prikazane koristi zdravila Micotil relativno na ostala odobrena protibakterijska sredstva, niso bili predloženi.
However, it is not possible on the basis of available evidence, to estimate a dose without adverse effects in human beings. 
Vendar na podlagi dostopnih dokazov ni možno oceniti odmerka brez neželenih učinkov pri človeku.
Given the diversity of farming conditions throughout the different EU Member States concerned by the referral, the various capabilities of farmers in the EU Member States concerned, as well as the recent trends in farming of more suckler animals and scarcity of labour in some EU Member States, the CVMP does not concur with the view of the representative of the MAHs that all ‘professional' farmers may be regarded as experienced and competent. 
Glede na raznolikost pogojev kmetovanja po državah članicah EU, ki jih zadeva postopek napotitve, različne zmogljivosti kmetov v zadevnih članicah EU ter nedavne trende v pretežnejši reji dojilj in pomanjkanje dela v nekaterih državah članicah EU, CVMP ne soglaša s pogledom predstavnika imetnikov dovoljenj za promet, da imamo lahko vse „profesionalne“ kmete za izkušene in usposobljene.
Tilmicosin was found to dosedependently reduce ICa amplitude with an IC50 value of 26.75 µM. 
Ugotovili so, da tilmikozin v odvisnosti od odmerka zmanjša amplitudo ICa z vrednostjo IC50 26,75 uM.
Very rarely the volume is higher than 1-2 ml and it is improbable that a fatality will occur. 
Zelo redko je volumen večji od 1-2 ml in smrtni primeri niso verjetni.
The risk : benefit analysis for Micotil is rather complex and various risk management proposals must be carefully considered. 
Analiza tveganja in koristi zdravila Micotil je precej zapletena, zato je treba natančno upoštevati različne predloge upravljanja s tveganjem.
Veterinary surgeons have specific training in drug safety, clinical medicine, animal husbandry, restraining and handling of animals. 
Veterinarji so specifično usposobljeni na področjih varnosti zdravil, klinične medicine, živinoreje, zadržanja in ravnanja z živalmi.
Single dose All sheep indications and pneumonia in cattle: 
En odmerek Vse indikacije pri ovcah in pljučnica pri govedu:
It is appreciated that this action would reduce the therapeutic armoury available for the effective treatment of diseases in animals. 
Ocenjeno je bilo, da bi ta ukrep zmanjšal terapevtske možnosti za učinkovito zdravljenje bolezni pri živalih.
ELANCO ELLAS Messogion 335 Av, 15231 Athens Greece 
ELANCO ELLAS Messogion 335 Av, 15231 Athens Grčija